BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37770957)

  • 1. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
    Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
    J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
    Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
    Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity.
    Arensman MD; Yang XS; Leahy DM; Toral-Barza L; Mileski M; Rosfjord EC; Wang F; Deng S; Myers JS; Abraham RT; Eng CH
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9533-9542. PubMed ID: 31019077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
    Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
    Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer.
    Lanzardo S; Conti L; Rooke R; Ruiu R; Accart N; Bolli E; Arigoni M; Macagno M; Barrera G; Pizzimenti S; Aurisicchio L; Calogero RA; Cavallo F
    Cancer Res; 2016 Jan; 76(1):62-72. PubMed ID: 26567138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
    Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
    Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues.
    Martis RM; Knight LJ; Donaldson PJ; Lim JC
    Oxid Med Cell Longev; 2020; 2020():4594606. PubMed ID: 32655769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
    Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glial Glutamate Transporter-Mediated Plasticity: System x
    Dahlmanns M; Dahlmanns JK; Savaskan N; Steiner HH; Yakubov E
    Front Biosci (Landmark Ed); 2023 Mar; 28(3):57. PubMed ID: 37005761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
    Lien EC; Ghisolfi L; Geck RC; Asara JM; Toker A
    Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of cystine/glutamate antiporter in multiple sclerosis.
    Pampliega O; Domercq M; Soria FN; Villoslada P; Rodríguez-Antigüedad A; Matute C
    J Neuroinflammation; 2011 Jun; 8():63. PubMed ID: 21639880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
    Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
    Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
    Habib E; Linher-Melville K; Lin HX; Singh G
    Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in glutamate and glutamine distributions in the retinas of cystine/glutamate antiporter knockout mice.
    Knight LJ; Martis RM; Donaldson PJ; Acosta ML; Lim JC
    Mol Vis; 2023; 29():274-288. PubMed ID: 38222448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation.
    Shih AY; Erb H; Sun X; Toda S; Kalivas PW; Murphy TH
    J Neurosci; 2006 Oct; 26(41):10514-23. PubMed ID: 17035536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses.
    Daher B; Parks SK; Durivault J; Cormerais Y; Baidarjad H; Tambutte E; Pouysségur J; Vučetić M
    Cancer Res; 2019 Aug; 79(15):3877-3890. PubMed ID: 31175120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of mice.
    Sato M; Onuma K; Domon M; Hasegawa S; Suzuki A; Kusumi R; Hino R; Kakihara N; Kanda Y; Osaki M; Hamada J; Bannai S; Feederle R; Buday K; Angeli JPF; Proneth B; Conrad M; Okada F; Sato H
    Int J Cancer; 2020 Dec; 147(11):3224-3235. PubMed ID: 32818320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astrocytes release glutamate via cystine/glutamate antiporter upregulated in response to increased oxidative stress related to sporadic amyotrophic lateral sclerosis.
    Kazama M; Kato Y; Kakita A; Noguchi N; Urano Y; Masui K; Niida-Kawaguchi M; Yamamoto T; Watabe K; Kitagawa K; Shibata N
    Neuropathology; 2020 Dec; 40(6):587-598. PubMed ID: 33305472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystine-glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice.
    Sprimont L; Janssen P; De Swert K; Van Bulck M; Rooman I; Gilloteaux J; Massie A; Nicaise C
    Sci Rep; 2021 Jun; 11(1):12227. PubMed ID: 34108554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter.
    Ruiu R; Rolih V; Bolli E; Barutello G; Riccardo F; Quaglino E; Merighi IF; Pericle F; Donofrio G; Cavallo F; Conti L
    Cancer Immunol Immunother; 2019 Jan; 68(1):131-141. PubMed ID: 29947961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.